P60-c-src suppresses apoptosis through inhibition of caspase 8 activation in hepatoma cells, but not in primary hepatocytes

Journal of Hepatology

Volumn 46, Issue 4, 2007, Pages 682-691

  De Toni, Enrico N ^a   Kuntzen, Christian ^a   Gerbes, Alexander L ^a   Thasler, Wolfgang E ^b   Sonuc, Nilüfer ^a   Mucha, Simon R ^a   Camaj, Peter ^a   Bruns, Christiane ^b   Göke, Burkhard ^a   Eichhorst, Sören T ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HCC; Src; TRAIL

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CASPASE 8; FAS ANTIGEN; PROTEIN KINASE P60; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL LINE; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION;

ANTIGENS, CD95; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 8; CELL CYCLE; CELL LINE; DRUG SYNERGISM; ENZYME ACTIVATION; GENOTYPE; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); PYRIMIDINES; RECEPTORS, CELL SURFACE; RNA, SMALL INTERFERING; SRC-FAMILY KINASES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33947187994     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.10.010     Document Type: Article

References (47)

1. El Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817-823
2. Eichhorst S.T., and Krammer P.H. Derangement of apoptosis in cancer. Lancet 358 (2001) 345-346
3. Eichhorst S.T. Modulation of apoptosis as a target for liver disease. Expert Opin Ther Targets 9 (2005) 83-99
4. Jaeschke H., and Lemasters J.J. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology 125 (2003) 1246-1257
5. Eichhorst S.T., Krueger A., Muerkoster S., Fas S.C., Golks A., Gruetzner U., et al. Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice. Nat Med 10 (2004) 602-609
6. Okano H., Shiraki K., Inoue H., Kawakita T., Yamanaka T., Deguchi M., et al. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 83 (2003) 1033-1043
7. Ito Y., Monden M., Takeda T., Eguchi H., Umeshita K., Nagano H., et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 82 (2000) 1211-1217
8. Shin M.S., Kim H.S., Lee S.H., Park W.S., Kim S.Y., Park J.Y., et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 61 (2001) 4942-4946
9. van Noesel M.M., van Bezouw S., Salomons G.S., Voute P.A., Pieters R., Baylin S.B., et al. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 62 (2002) 2157-2161
10. Ozoren N., and El Deiry W.S. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 13 (2003) 135-147
11. Schuchmann M., and Galle P.R. Sensitizing to apoptosis - sharpening the medical sword. J Hepatol 40 (2004) 335-336
12. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104 (1999) 155-162
13. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6 (2000) 564-567
14. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7 (2001) 383-385
15. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5 (1999) 157-163
16. Ganten T.M., Haas T.L., Sykora J., Stahl H., Sprick M.R., Fas S.C., et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11 (2004) S86-S96
17. Iravani S., Mao W., Fu L., Karl R., Yeatman T., Jove R., et al. Elevated c-Src protein expression is an early event in colonic neoplasia. Lab Invest 78 (1998) 365-371
18. Irby R.B., and Yeatman T.J. Role of Src expression and activation in human cancer. Oncogene 19 (2000) 5636-5642
19. Masaki T., Okada M., Shiratori Y., Rengifo W., Matsumoto K., Maeda S., et al. pp60c-src activation in hepatocellular carcinoma of humans and LEC rats. Hepatology 27 (1998) 1257-1264
20. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139 (1991) 271-279
21. Ganten T.M., Koschny R., Haas T.L., Sykora J., Li-Weber M., Herzer K., et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42 (2005) 588-597
22. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17 (1998) 1675-1687
23. Krueger A., Schmitz I., Baumann S., Krammer P.H., and Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276 (2001) 20633-20640
24. Thasler W.E., Weiss T.S., Schillhorn K., Stoll P.T., Irrgang B., and Jauch K.W. Charitable state-controlled foundation human tissue and cell research: ethic and legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell Tissue Bank 4 (2003) 49-56
25. Weiss T.S., Pahernik S., Scheruebl I., Jauch K.W., and Thasler W.E. Cellular damage to human hepatocytes through repeated application of 5-aminolevulinic acid. J Hepatol 38 (2003) 476-482
26. Yezhelyev M.V., Koehl G., Guba M., Brabletz T., Jauch K.W., Ryan A., et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 10 (2004) 8028-8036
27. Chang R.S. Continuous subcultivation of epithelial-like cells from normal human tissues. Proc Soc Exp Biol Med 87 (1954) 440-443
28. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 271 (1996) 695-701
29. Moasser M.M., Srethapakdi M., Sachar K.S., Kraker A.J., and Rosen N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res 59 (1999) 6145-6152
30. Fukuhara T., Shimizu K., Kawakatsu T., Fukuyama T., Minami Y., Honda T., et al. Activation of Cdc42 by trans interactions of the cell adhesion molecules nectins through c-Src and Cdc42-GEF FRG. J Cell Biol 166 (2004) 393-405
31. Cussac D., Greenland C., Roche S., Bai R.Y., Duyster J., Morris S.W., et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 103 (2004) 1464-1471
32. Cursi S., Rufini A., Stagni V., Condo I., Matafora V., Bachi A., et al. Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J 25 (2006) 1895-1905
33. Blake R.A., Broome M.A., Liu X., Wu J., Gishizky M., Sun L., et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 20 (2000) 9018-9027
34. Golas J.M., Arndt K., Etienne C., Lucas J., Nardin D., Gibbons J., et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63 (2003) 375-381
35. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69 (1992) 11-25
36. Noritake H., Miyamori H., Goto C., Seiki M., and Sato H. Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src. Clin Exp Metastasis 17 (1999) 105-110
37. Belka C., Gruber C., Jendrossek V., Wesselborg S., and Budach W. The tyrosine kinase Lck is involved in regulation of mitochondrial apoptosis pathways. Oncogene 22 (2003) 176-185
38. Reinehr R., Becker S., Hongen A., and Haussinger D. The Src family kinase Yes triggers hyperosmotic activation of the epidermal growth factor receptor and CD95. J Biol Chem 279 (2004) 23977-23987
39. Park S.S., Eom Y.W., Kim E.H., Lee J.H., Min D.S., Kim S., et al. Involvement of c-Src kinase in the regulation of TGF-beta1-induced apoptosis. Oncogene (2004)
40. Griffiths G.J., Koh M.Y., Brunton V., Cawthorne C., Reeves N.A., Greaves M., et al. Expression of kinase defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-XL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem (2004)
41. Roche S., Fumagalli S., and Courtneidge S.A. Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division. Science 269 (1995) 1567-1569
42. Jones R.J., Avizienyte E., Wyke A.W., Owens D.W., Brunton V.G., and Frame M.C. Elevated c-Src is linked to altered cell-matrix adhesion rather than proliferation in KM12C human colorectal cancer cells. Br J Cancer 87 (2002) 1128-1135
43. Lee M., Kim J.Y., and Koh W.S. Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia. J Cell Biochem 93 (2004) 629-638
44. Sefton B.M., Trowbridge I.S., Cooper J.A., and Scolnick E.M. The transforming proteins of Rous sarcoma virus, Harvey sarcoma virus and Abelson virus contain tightly bound lipid. Cell 31 (1982) 465-474
45. Owen-Schaub L.B., Zhang W., Cusack J.C., Angelo L.S., Santee S.M., Fujiwara T., et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15 (1995) 3032-3040
46. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
47. Yeatman T.J. A renaissance for SRC. Nat Rev Cancer 4 (2004) 470-480